Abstract
Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic inflammation within the gastrointestinal tract. It is a multifactorial disease associated with immune-cell mediated oxidative damage to the intestinal mucosa. There is no cure for IBD, but anti-cytokine therapy can limit target inflammation and disease progression. Unfortunately, many patients are nonresponsive or develop resistance to anti-cytokine therapy over time creating a need for new therapeutic agents. Metallothionein (MT) is a small, highly conserved stress response protein that has been shown to modulate the immune response as a pro-inflammatory agent, regulates divalent heavy metal homeostasis, and acts as a reactive metabolite scavenger. Our research, as well as other groups studying MT, has described MT induction and release during IBD inflammatory stress response. The release of MT results in activation of inflammatory responses leading to progressive inflammation and subsequent expansion of MT synthesis. A monoclonal antibody specific for MT has been used in murine models of IBD and should only target the extracellular pool of MT, thus representing a novel therapeutic approach to this disease.
Keywords: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Metallothionein, biologic therapy, inflammation.
Current Pharmaceutical Design
Title:Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease
Volume: 24 Issue: 27
Author(s): Kristen E. Dostie, Amy V. Thees and Michael A. Lynes*
Affiliation:
- Department of Molecular and Cell Biology, University of Connecticut, Storrs,United States
Keywords: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Metallothionein, biologic therapy, inflammation.
Abstract: Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic inflammation within the gastrointestinal tract. It is a multifactorial disease associated with immune-cell mediated oxidative damage to the intestinal mucosa. There is no cure for IBD, but anti-cytokine therapy can limit target inflammation and disease progression. Unfortunately, many patients are nonresponsive or develop resistance to anti-cytokine therapy over time creating a need for new therapeutic agents. Metallothionein (MT) is a small, highly conserved stress response protein that has been shown to modulate the immune response as a pro-inflammatory agent, regulates divalent heavy metal homeostasis, and acts as a reactive metabolite scavenger. Our research, as well as other groups studying MT, has described MT induction and release during IBD inflammatory stress response. The release of MT results in activation of inflammatory responses leading to progressive inflammation and subsequent expansion of MT synthesis. A monoclonal antibody specific for MT has been used in murine models of IBD and should only target the extracellular pool of MT, thus representing a novel therapeutic approach to this disease.
Export Options
About this article
Cite this article as:
Dostie E. Kristen , Thees V. Amy and Lynes A. Michael *, Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease, Current Pharmaceutical Design 2018; 24 (27) . https://dx.doi.org/10.2174/1381612824666180717110236
DOI https://dx.doi.org/10.2174/1381612824666180717110236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Involvement of Mast Cells in Angiogenesis and Chronic Inflammation
Current Drug Targets - Inflammation & Allergy Designed Ankyrin Repeat Proteins: A Look at their Evolving Use in Medicine with a Focus on the Treatment of Chorioretinal Vascular Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metabolic Pathways of Ochratoxin A
Current Drug Metabolism The Effects of Bisphosphonates on the Bone Marrow Niche and Circulating and Disseminated Tumor Cells
Current Cancer Therapy Reviews Topical Formulations and Intradermal Injections of Tranexamic Acid in the Treatment of Hyperpigmentation - A Review
Letters in Drug Design & Discovery Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Current Neuropharmacology Custom DNA-Binding Proteins and Artificial Transcription Factors
Current Topics in Medicinal Chemistry Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?
Current Medicinal Chemistry Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
Current Diabetes Reviews Yokukansan, a Japanese Herbal Medicine, Suppresses Substance P-Induced Production of Interleukin-6 and Interleukin-8 by Human U373 MG Glioblastoma Astrocytoma Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models
CNS & Neurological Disorders - Drug Targets Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry RNA Interference and Potential Applications
Current Topics in Medicinal Chemistry HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Electron Paramagnetic Resonance (EPR) Spectroscopy: A Versatile and Powerful Tool in Pharmaceutical and Biomedical Analysis
Current Pharmaceutical Analysis S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics